curiculum vitae - the medical university of south …people.musc.edu/~nab42/baker, nl cv.pdf ·...

Baker, Nathaniel L

- 1 - Last Updated 1/9/2018

CURICULUM VITAE

Name: Nathaniel L Baker Office Address: 135 Cannon Street Suite 303 Charleston, SC 29425 Office Phone: 843‐792‐5028 Office Email: [email protected] Citizenship and/or Visa Information: USA Education: Institution Years Degree/Date Field of Study Georgia Regents University (Former Augusta State U) 1999‐2005 B.S. 2005 Mathematics Georgia Regents University (Former Medical Col of GA) 2006‐2008 M.S. 2008 Biostatistics GPA: 3.75/4.00 Thesis: A Regression Based Transmission/Disequilibrium Test for Quantitative Traits using Sib‐Pair

Family Data; Faculty Appointments: Years Rank Institution Department 2012‐ Research Instructor MUSC Dept of Public Health Sciences 2008‐2012 Research Associate MUSC Dept of Biostatistics, Bioinformatics and Epidemiology Administrative Appointments: Years Position Institution Department None Other Experience: Years Position Institution Department 2006‐2008 Grad Res Assistant GRU/MCG Biostatistics 2005‐2006 Mathematics Inst. Heph HS Mathematics 2005 Lab Assistant ASU Chemistry and Physics 2002‐2005 Lab Assistant ASU Mathematics and Computer Science Membership in Professional organizations Current 2017‐Present American Diabetes Association Past 2006‐2010 American Statistical Association 2006‐2013 Southeast SAS Users Group SC Chapter 2004‐2005 ASU Physics Society 2003‐2005 Mathematical Association of America 2000‐2005 ASU Euclidean Society Positions Held: President (2004‐2005)

Baker, Nathaniel L


Editorial Positions: 2011‐2013 Review Editor: Frontiers in Applied Genetic Epidemiology (Frontiers) 2012‐ Reviewer: Journal of Child and Adolescent Substance Abuse 2015‐ Reviewer: PLOS ONE 2016‐ Reviewer: Journal of Smoking Cessation 2016‐ Reviewer: Drug and Alcohol Dependence Major Teaching Responsibilities: None Major Clinical Interests and Responsibilities: None University/Departmental Committee Membership 2016‐2017 Dept. of Public Health Sciences RA/RI Promotion Development Committee 2008‐2016 Dept. of Public Health Sciences Social Committee (Chair 2011‐2014) 2013 Dept. of Public Health Sciences IYOS Committee DSMB Membership 2011‐2016: COPE Study (HR # 20279), PI Sudie Back, Department of Psychiatry 2012‐2015: SNUS Study (R01CA154992‐02), PI Matthew Carpenter, Department of Psychiatry 2104‐Present: TIP TOP Study (R01), PI Matthew Carpenter, Department of Psychiatry Lectures and Presentations: Contributed Talks, Lectures, and Posters Authored by Nathaniel L Baker 1. Nathaniel L Baker, Rickey E Carter. Biomarker Relationships with Nephropathy outcomes in Type I Diabetes patients in the EDIC study. (Oral Presentation) Presented to the MUSC EDIC study group. Charleston, SC, July, 2009 2. Nathaniel L Baker Jittering: A SAS® Macro to Shift Overlapping Plots. (Oral Presentation) Presented at the South East SAS Users Group, Birmingham, AL, October, 2009.

3. Nathaniel L Baker. Estimating Stratified two Factor Interactions in a 3 Factor Design in SAS Proc Mixed. (Oral Presentation) Presented to the DBE Collaborative Unit, Medical University of South Carolina, Charleston, SC, January, 2011. 4. Nathaniel L Baker. An Introduction to Graphics in SAS. (Oral Presentation) Presented as a Guest Lecturer Biometry 789‐02, Computing for Research, DBE, Medical University of South Carolina, January, 2011

5. Nathaniel L Baker. Analysis of Coronary Artery Calcification Data: Modeling Considerations. Presented at Tea Time for Science, DBE, Medical University of South Carolina, April, 2011

Baker, Nathaniel L


6. Nathaniel L Baker, Maria F Lopes‐Virella, Kelly J Hunt, Gabriel Virella. Oxidized LDL immune complex and the progression of retinopathy in Type 1 diabetes. (Oral Presentation) Presented at the 71st American Diabetes Association Scientific Session, San Diego, CA, June, 2011. 7. Nathaniel L Baker, Kelly J Hunt, Tim Lyons, Rick Klein, Patricia A Cleary, Gabe Virella, Maria F Lopes‐

Virella, and the DCCT group of investigators. Markers of inflammation are associated with development of abnormal albuminuria in Type 1 Diabetics. (Oral Presentation) American Diabetes Association 72nd Scientific Session, Philadelphia PA, June 2012

8. Nathaniel L Baker. Statistical Graphics for the SAS System. (Oral Presentation) Presented as a Guest Lecturer Biometry 789‐02, Computing for Research, DBE, Medical University of South Carolina, January, 2013

9. Nathaniel L Baker, Kelly J Hunt, Richard L Klein, Samar M Hammad, Mohammed M. Al Gabdan, Gabe

Virella, Maria F Lopes‐Virella, and the DCCT/EDIC group of Investigators. Plasma levels of very long chain ceramide species are associated with decreased odds of Macroalbuminuria. (Poster Presentation) 73rd Scientific Session of the American Diabetes Associations, Chicago, IL, June, 2013.

10. Nathaniel L Baker. Statistical Graphics for the SAS System. (Oral Presentation) Presented as a Guest Lecturer Biometry 789‐02, Computing for Research, DBE, Medical University of South Carolina, January, 2014

11. Nathaniel L Baker, Paul J Nietert. A Picture is Worth a Thousand Words: Graphical Display of Data and

Statistical Analysis for Clinical Research. (Invited Oral Presentation) Presented for the MUSC Apple Tree Society, Medical University of South Carolina, April, 2014

12. Nathaniel L Baker, Courtney McCracken. Statistical Consulting in Medical Research. Presented as a

Guest Lecturer STAT 8870, Biostatistics Consulting in Research, Department of Biostatistics and Epidemiology, Georgia Regents University, June 2014

13. Nathaniel L Baker, Maria F Lopes‐Virella, Kelly J Hunt, Patricia A Cleary, Richard Klein, Gabriel Virella, DCCT/EDIC Research Group. Change in biomarkers of inflammation according to development and progression of albuminuria. (Poster Presentation) 75th Scientific Session of the American Diabetes Associations, Boston, MA June, 2015.

14. Nathaniel L Baker, Kelly J Hunt, Richard L Klein, Samar M Hammad, Gabriel Virella, Maria Lopes‐Virella

and the DCCT/EDIC Research Group. The Association of Prevalent Macroalbuminuria with Levels of Sphingolipids and Glycosphingolipids at the end of the DCCT Study. (Poster Presentation) 76th Scientific Session of the American Diabetes Associations, New Orleans, LA., June 2016.

15. Nathaniel L Baker. Statistical Implications in Cannabis Use Outcome Determination. (Invited Presentation) NIDA Clinical Trials Endpoints of Therapeutics for Cannabis Use Disorder Working Group Meeting, Bethesda, MD, September 2016.

16. Nathaniel L Baker, Kelly J Hunt, Danielle R Stevens, Richard L Klein, Gabriel Virella, Maria F Lopes‐Virella and the DCCT/EDIC Research Group. Inflammatory markers and progression to kidney dysfunction: different assessment windows in type 1 diabetic subjects. (Poster Presentation) 77th American Diabetes Association Scientific Session, San Diego, CA, June 2017.

Baker, Nathaniel L


Publications: Peer Reviewed Journal Articles Published/Accepted: 1. Abid Irshad, Susan J. Ackerman, Munazza Anis, Amy S. Campbell, Atif Hashmi, Nathaniel L. Baker. Can the smallest depth of ascitic fluid on sonograms predict the amount of drainable fluid? Journal of Clinical Ultrasound. 2009 October; 37 (8): 440‐444.

2. Sudie E Back, Karen Hartwell, Stacia M DeSantis, Michael E Saladin, Aimee L McRae‐Clark, Kimber L Price, Megan M Moran‐Santa Maria, Nathaniel L Baker, Eve Spratt, Mary Jeanne Kreek, Kathleen T Brady. Reactivity to Laboratory Stress Provocation Predicts Relapse to Cocaine. Drug and Alcohol Dependence. 2010 January; 106 (1): 21‐27. 3. Brian K. Tolliver, Aimee McRae‐Clark, Michael Saladin, Kimber L Price, Annie N Simpson, Stacia M Desantis, Nathaniel L Baker, Kathleen T Brady. Determinants of Cue‐Elicited Craving and Physiologic Reactivity in Methamphetamine‐Dependent Subjects in the Laboratory. The American Journal of Drug and Alcohol Abuse. 2010 March; 36 (2): 106‐113 4. Kevin M Gray, Nathaniel L Baker, Matthew J Carpenter, A. Lee Lewis, & Upadhyaya, H. P. Attention‐Deficit/Hyperactivity Disorder (ADHD) Confounds Nicotine Withdrawal Self‐Report in Adolescent Smokers. American Journal on Addictions. 2010 July; 19 (4): 325‐331 5. Kimber L Price, Michael E Saladin, Nathaniel L Baker, Bryan K Tolliver, Stacia M DeSantis, Aimee McRae‐ Clark, Kathleen T Brady. Extinction of Drug Cue Reactivity in Methamphetamine‐Dependent Individuals. Behaviour Research and Therapy. 2010 September; 48: 860‐865 6. Megan M Moran‐Santa Maria, Aimee L McRae‐Clark, Sudie E Back, Stacia M DeSantis, Nathaniel L Baker, Eve G Spratt, Annie N Simpson, Kathleen T Brady. Influence of Cocaine Dependence and Early Life Stress on Pituitary‐Adrenal Axis Responses to CRH and the Trier Social Stressor. Psychoneuroendocrinology. 2010 November; 35: 1492‐1500. 7. Matthew J Carpenter, Nathaniel L Baker, Kevin M Gray, Himanshu P Uapdhyaya. Assessment of Nicotine Dependence among Adolescent and Young Adult Smokers: A Comparison of Measures. Addictive Behaviors. 2010 November; 35: 977‐982 8. Kevin M Gray, Matthew J Carpenter, Nathaniel L Baker, Karen J Hartwell, A Lee Lewis, D. Walter Hiott, Deborah Deas, Himanshu P Upadhyaya. Bupropion SR and Contingency Management for Adolescent Smoking Cessation: A Randomized, Double Blind, Placebo‐Controlled Trial. Journal of Substance Abuse Treatment. 2011 January; 40: 77‐86. 9. Maria F Lopes‐Virella, Nathaniel L Baker, Kelly J Hunt, John Lachin, David M Nathan, Gabriel Virella, and the DCCT/EDIC Research Group. Oxidized LDL Immune Complexes and Coronary Artery Calcification in Type 1 Diabetes. Atherosclerosis. 2011 February; 214: 462‐467

Baker, Nathaniel L


10. Maria F Lopes‐Virella, Kelly J Hunt, Nathaniel L Baker, John Lachin, David M Nathan, Gabriel Virella, and the DCCT/EDIC Research Group. Oxidized LDL and AGE‐ LDL Immune Complexes Strongly Predict the Development of Vascular Disease in Type 1 Diabetes. Diabetes. 2011 February; 60: 582‐589.

11. Richard L Klein, Rickey E Carter, Alicia J Jenkins, Timothy J Lyons, Nathaniel L Baker, Gregory E Gilbert, Gabriel Virella, Maria F Lopes‐Virella and the DCCT/EDIC Research Group. LDL‐Containing Immune Complexes in the DCCT/EDIC Cohort: Associations with Lipoprotein Subclasses. Journal of Diabetes and its Complications. 2011 March; 25: 73‐82. 12. Stacia M DeSantis, Nathaniel L Baker, Sudie E Back, Eve G Spratt, Jody D Ciolino, Megan M Moran‐ Santa Maria, Dipankar Bandyopadhya, Kathleen T Brady. Gender differences in the Effect of Early Life Trauma on HPA Axis Functioning. Depression and Anxiety. 2011 May; 28: 383‐392. 13. Jennifer A Dixon, Robert C Gorman, Robert E Stroud, Rupak Mukherjee, Evan C Meyer, Nathaniel L Baker, Masoto Morita, Hirotsugu Hamamoto, Liam P Ryan, Joseph H Gorman, Francis G Spinale. Targeted Regional Injection of Biocomposite Microspheres Alters Post‐Myocardial Infarction Remodeling and Matrix Proteoytic Pathways. Circulation. 2011 September; 124:S35‐S45 14. Kimber L Price, Stacia M DeSantis, Annie N Simpson, Brian K Tolliver, Aimee McRae‐Clark, Michael E Saladin, Nathaniel L Baker, Mark Wagner, Kathleen T Brady. The Impact of Clinical and Demographic Variables on Cognitive Performance in Methamphetamine‐dependent Individuals in Rural South Carolina. American Journal on Addictions. 2011 September; 20; 447‐455. 15. Aimee L McRae‐Clark, Rickey E Carter, Kimber L Price, Nathaniel L Baker, Suzanne Thomas, Kathleen Giarla, Katherine Nicholas, Kathleen T Brady. Stress and Cue‐Elicited Craving and Reactivity in Marijuana‐Dependent Individuals. Psychopharmacology. 2011 November; 218:49‐58. 16. Jennifer A Dixon, Amy M Goodman, William F Gaillard, William T Rivers, Richard A McKinney, Rupak Mukherjee, Nathaniel L Baker, John S Ikonomidis, Francis G Spinale. Hemodynamics and Myocardial Blood Flow Patterns after Placement of a Cardiac Passive Restraint Device in a Model of Dilated Cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery. 2011 November; 142 (5): 1038‐ 1045. 17. Abid Irshad, Susan J Ackerman, Kenneth M Spicer, Nathaniel L Baker, Amy S Campbell, Anis Munazza, Mehwish Shazly. Ultrasound Evaluation of Gallbladder Dyskinesia: Comparison of Scintigraphy and Dynamic 3D and 4D Ultrasound Techniques. The American Journal of Roentgenology. 2011 November; 197 (5): 1103‐1110.

18. Eric M Graham, Andrew M Atz, Ryan J Butts, Nathaniel L Baker, Sinai C Zyblewski, Rachael L Deardorff, Stacia M DeSantis, Scott T Reeves, Scott M Bradley, Francis G Spinale. Standardized Preoperative Corticosteroid Treatment in Neonates undergoing Cardiac Surgery‐Results from a Randomized Trial. The Journal of Thoracic and Cardiovascular Surgery. 2011 December; 142 (6): 1523‐ 1529. 19. Maria F Lopes‐Virella, Rickey E Carter, Nathaniel L Baker, Gabriel Virella, and the DCCT/EDIC Research Group High Levels of Oxidized LDL‐Immune Complexes Are Associated With Increased Odds To Develop Nephropathy In Type 1 Diabetes. Nephrology Dialysis Transplantation. 2012 April; 27(4): 1426‐1423.

Baker, Nathaniel L


20. Bryan K Tolliver, Kimber L Price, Nathaniel L Baker, Steven D LaRowe, Annie N Simpson, Aimee L McRae‐

Clark, Michael E Saladin, Stacia M DeSantis, Kathleen T Brady. Impaired Cognitive Performance in Subjects with Methamphetamine Dependence During Exposure to Neutral Versus Methamphetamine‐Related Cues. The American Journal of Drug and Alcohol Abuse. 2012 May; 38(3): 251‐259.

21. Maria F Lopes‐Virella, Nathaniel L Baker, Kelly J Hunt, Timothy J Lyons, Alicia Jenkins, Gabriel Virella,

and the DCCT/EDIC Research Group. High Concentrations of AGE‐LDL and Oxidized LDL in Circulating Immune Complexes are Associated with Progression of Retinopathy in Type 1 Diabetes. Diabetes Care. 2012 June; 35: 1333‐1340.

22. Kevin M. Gray, Matthew J. Carpenter, Nathaniel L. Baker, Stacia M DeSantis, Elisabeth Kryway, Karen J Hartwell, Aimee L McRae‐Clark, Kathleen T Brady. A double‐blind randomized controlled trial of N‐ Acetylcysteine in cannabis dependent adolescents. American Journal of Psychiatry. 2012 August 169; 8: 805‐812. 23. Maria F Lopes‐Virella, Kelly J Hunt, Nathaniel L Baker, Thomas Moritz, Gabriel Virella, and the VADT group of Investigators. The Levels of MDA – LDL in Circulating Immune Complexes predict Myocardial Infarction in the VADT study. Atherosclerosis. 2012 October; 224:526‐531. 24. Gabriel Virella, Joan Colglazier, Charlyne Chassereau, Kelly Hunt, Nathaniel Baker, Maria Lopes‐Virella. Immunoassay of Modified Forms of Human Low Density Lipoprotein in Isolated Circulating Immune Complexes. Journal of Immunoassay and Immunochemistry. 2013 January; 34 (1):61‐74. 25. Abid Irshad, Rebecca J Leddy, Etta D Pisano, Nathaniel L Baker, Madelene C Lewis, Susan J Ackerman, Amy S Campbell. Assessing the role of ultrasound in predicting the biological behavior of breast cancers. The American Journal of Roentgenology. 2013 February; 200: 284‐290. 26. Amanda T Roten, Nathaniel L Baker, Sudie Back, Kevin M Gray. Marijuana Craving Trajectories in an Adolescent Marijuana Cessation Pharmacotherapy Trial. Addictive Behaviors. 2013 March; 38:1788‐ 1791. 27. Michael E. Saladin, Kevin M. Gray, Aimee L. McRae‐Clark, Steven D. LaRowe, Sharon D. Yeatts, Nathaniel L Baker, Karen J. Hartwell, and Kathleen T. Brady. A Double Blind, Placebo‐Controlled Study of the Effects of Post‐Retrieval Propranolol on Reconsolidation of Memory for Craving and Cue Reactivity in Cocaine Dependent Humans. Psychopharmacology. 2013 April; 226 (4): 721‐737 28. Kimber L Price, Nathaniel L Baker, Aimee McRae‐Clark, Michael E Saladin, Stacia M DeSantis, Elizabeth

Santa Ana, Kathleen T Brady. A Randomized, Placebo‐controlled Laboratory Study of the Effects of D‐cycloserine on Craving in Cocaine‐Dependent Individuals. Psychopharmacology. 2013 April; 226 (4): 739‐746

29. Maria F Lopes‐Virella, Nathaniel L Baker, Kelly J Hunt, Patricia A Cleary, Richard Klein, Gabriel Virella,

and the DCCT/EDIC Research Group. Baseline Markers of Inflammation are Associated with Progression to Macroalbuminuria in Type 1 Diabetic Subjects. Diabetes Care. 2013 August; 36 (8); 2317‐2323.

30. Aimee L McRae‐Clark, Nathaniel L Baker, Megan Moran‐Santa Maria, Kathleen T Brady. Effect of Oxytocin on Craving and Stress Response in Marijuana‐Dependent Individuals: A Pilot Study. Psychopharmacology. 2013 August; 228:623‐632.

Baker, Nathaniel L


31. Stacia M DeSantis, Dipankar Bandyopadhyay, Nathaniel L Baker, Patrick Randall, Raymond Anton, Jim J Prisciandaro. Modeling Longitudinal Data in Substance Use Clinical Trials: An Application to the COMBINE Study. Drug and Alcohol Dependence. 2013 September; 132:244‐250. 32. Alicia J Jenkins, Jeremy Yu, Petar Alaupovic , Arpita Basu, Richard L Klein, Maria Lopes‐Virella, Nathaniel

L Baker, Kelly J Hunt, Daniel T Lackland, W. Timothy Garvey, , Timothy J Lyons, and the DCCT/EDIC Research Group. Apolipoprotein‐defined Lipoproteins and Apolipoproteins: Associations with Abnormal Albuminuria in Type 1 Diabetes (DCCT/EDIC Cohort). Journal of Diabetes and its Complications. 2013 September; 27:447‐453.

33. A. Lee Lewis, Nathaniel Baker, Matthew Carpenter, Erin Klintworth, Kevin M Gray. Does physician

continuity within a clinical trial increase retention and compliance among adolescent smokers? Adolescent Psychiatry. 2013; 3:195‐9.*

34. Erin A McClure, Michael E Saladin, Nathaniel L Baker, Matthew J Carpenter, and Kevin M Gray. Smoking

topography and abstinence in adult female smokers. Addictive Behaviors. 2013 December; 38:2833‐2836.

35. Kelly J Hunt, Nathaniel L Baker, Patricia Cleary, Jye‐Yu Backlund, Gabriel Virella, Maria F Lopes‐Virella, and the DCCT /EDIC Research Group. Oxidized LDL and AGE‐LDL in Circulating Immune Complexes strongly Predicts Progression of Internal Carotid Artery IMT in Type 1 Diabetes. Atherosclerosis. 2013 December; 231:315‐322.

36. Eric M Graham, Andrew M Atz, Kimberly E McHugh, Ryan J Butts, Nathaniel L Baker, Robert E Stroud,

Rachael L Deardorff, Scott T Reeves, Scott M Bradley, Francis X McGowan, Jr., Francis G Spinale. Preoperative Steroid Treatment Does Not Improve Markers of Inflammation Following Cardiac Surgery in Neonates. The Journal of Thoracic and Cardiovascular Surgery. 2014 March; 147(3): 902‐908.

37. Maria F Lopes‐Virella, Nathaniel L Baker, Kelly J Hunt, Patricia A Cleary, Richard Klein, Gabriel Viralla,

and the DCCT/EDIC Research Group. Response to comment on Lopes‐Virella et al. baseline marker of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2014, May; 37(5): e108‐e109.

38. Erin A McClure, Nathaniel L Baker, Kevin M Gray. Cigarette smoking during an N‐acetylcysteine‐assisted

cannabis cessation trial in adolescents. The American Journal of Drug and Alcohol Abuse. 2014 July; 40(4): 285‐291.

39. Richard L Klein, Samar M Hammad, Nathaniel L Baker, Kelly J Hunt, Mohammed M Al Gadban, Patricia A

Cleary, Gabe Virella, Maria F Lopes‐Virella, and the DCCT/EDIC Research Group. Decreased Plasma Levels of Select Very Long Chain Ceramide Species are Associated with The Development of Nephropathy in Type 1 Diabetes. Metabolism. 2014 October; 63:1287‐1295.

40. Megan Moran Santa‐Maria, Aimee McRae‐Clark, Nathaniel L Baker, Viswanathan Ramakrishnan,

Kathleen T Brady. Yohimbine Administration and Cue‐Reactivity in Cocaine Dependent Individuals . Psychopharmacology. 2014 October; 231 (21); 4157‐4165.

Baker, Nathaniel L


41. Erin A McClure, Nathaniel L Baker, Cassandra D Gipson, Matthew J Carpenter, Amanda Roper, Brett Froeliger, Peter W Kalivas, Kevin M Gray. An Open Label Pilot Trial of N‐acetylcysteine and Varenicline in Adult Cigarette Smokers. The American Journal of Drug and Alcohol Abuse. 2015 January; 41(1): 52‐56.

42. Hussein A Rajab, Nathaniel L Baker, Kelly J Hunt, Richard Klein, Patricia A Cleary, Gabriel Virella, Maria F

Lopes‐Virella, and the DCCT/EDIC group of Investigators. The Predictive Role of Markers of Inflammation and Endothelial Dysfunction on the course of diabetic Retinopathy in Type 1 Diabetics Subjects. The Journal of Diabetes and its Complications. 2015 January; 29:108‐114.

43. Amanda T Roten, Nathaniel L Baker, Alan Boyd, Kevin M Gray. Cognitive Performance in a Placebo‐

Controlled Pharmacotherapy Trial for Youth with Marijuana Dependence. Addictive Behaviors. 2015 June; 45:119‐123.

44. Megan Moran Santa‐Maria, Nathaniel L Baker, Viswanathan Ramakrishnan, Aimee McRae‐Clark,

Kathleen T Brady. Impact of acute guanfacine administration on stress and cue reactivity in cocaine‐dependent individual. The American Journal of Drug and Alcohol Abuse. 2015 March; 41(2): 146‐152.

45. Michael E Saladin, Erin A McClure, Nathaniel L Baker, Matthew J Carpenter, Viswanathan Ramakrishnan, Karen J Hartwell, Kevin M Gray. Increasing Progesterone Levels are Associated with Smoking Abstinence in Free Cycling Women Smokers Receiving Brief Pharmacotherapy. Nicotine and Tobacco Research. 2015 April; 17(4):398‐406.

46. Cheryl P Lynch, Nathaniel L Baker, Jeffrey E Korte, Jill G Mauldin, Maria E Mayorga, Kelly J Hunt. Increasing Prevalence of Diabetes During Pregnancy in South Carolina. Journal of Women’s Health. 2015 April; 24(4): 316‐323.

47. Leonardo Bonilha, Jens H Jensen, Nathaniel L Baker, Jesse L Breedlove, Travis Nesland, Jack J Lin, and

Daniel L Drane. The Brain Connectome as a Personalized Biomarker of Seizure Outcomes after Temporal Lobectomy. Neurology 2015 May; 84(18): 1846‐1853.

48. Kevin M Gray, Erin A McClure, Nathaniel L Baker, Matthew J Carpenter, Michael E Saladin, Viswanathan

Ramakrishnan, and Kathleen T Brady. An Exploratory short‐term double blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. Addiction 2015 June; 110: 1027‐1034.

49. Kelly J Hunt, Nathaniel L Baker, Patricia A Cleary, Richard Klein, Gabriel Virella, Maria F Lopes‐Virella,

and the DCCT/EDIC Research Group. Longitudinal association between endothelial dysfunction, inflammation and clotting biomarkers with subclinical atherosclerosis in type 1 diabetes: an evaluation of the DCCT/EDIC cohort. Diabetes Care 2015 July; 38:1281‐1289.

50. Julianne C Flanagan, Nathaniel L Baker, Aimee L McRae‐Clark, Kathleen T Brady, & Megan M Moran Santa‐Maria. The Effect of Adverse Childhood Experiences on the Association between Intranasal Oxytocin and Social Stress Reactivity among Individuals with Cocaine Dependence. Psychiatry Research 2015 September; 229:94‐100;

51. Aimee L McRae‐Clark, Nathaniel L Baker, Susan C Sonne, C Lindsay DeVane, Amanda Wagner, and

Jessica Norton. Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence. The Journal of Substance Abuse Treatment 2015 October; 57:70‐74.

Baker, Nathaniel L


52. Aimee L McRae‐Clark, Nathaniel L Baker, Kevin M Gray, Therese K Killeen, Amanda M Wagner, Kathleen T Brady, Lindsay C DeVane, Jessica Norton. Buspirone treatment of cannabis dependence: a randomized, controlled trial. Drug and Alcohol Dependence 2015 November; 156:29‐37.

53. Aimee L McRae‐Clark, Nathaniel L Baker, Kevin M Gray, Therese K Killeen, Amanda M Wagner, C Lindsay

DeVane, and Jessica Norton. Vilazadone for Cannabis Dependence: a Randomized, Controlled Pilot Trial. The American Journal on Addictions 2016 January; 25(1):69‐75.

54. Megan M. Moran‐Santa Maria, Nathaniel L Baker, Aimee L. McRae‐Clark, James J Priciandaro, Kathleen

T Brady. Effects of Yohimbine and Drug Cues on Impulsivity and Attention in Cocaine‐Dependent Individuals. Drug and Alcohol Dependence 2016 May; 162:56‐63.

55. Maria F Lopes‐Virella, Kelly J Hunt, Nathaniel L Baker, Gabriel Virella, VADT Research Group. High levels

of AGE‐LDL, and of IgG Antibodies reacting with MDA‐lysine epitompes expressed by OxLDL and MDA‐LDL in Circulating Immune Complexes Predict Macroalbuminuria in Patients with Type 2 Diabetes. Journal of Diabetes and its Complications 2016 May‐June; 30:693‐699.

56. Brian Sherman, Nathaniel L Baker, Aimee L McRae‐Clark. Gender Differences in Cannabis use Disorder

Treatment: Change Readiness and Taking Steps Predict Worse Cannabis Outcomes for Women. Addictive Behaviors 2016;60 (197‐202).

57. Lindsay M Squeglia, Nathaniel L Baker, Erin A McClure, Rachel L Tomko, Vitria Adisetiyo, Kevin M Gray.

Alcohol use during a trial of N‐acetylcysteine for adolescent marijuana cessation. Addictive Behaviors 2016;63 (172‐177).

58. Rachel L Tomko, Michael E Saladin, Erin A McClure, Lindsay M Squeglia, Matthew J Carpenter, Stephen S

Tiffany, Nathaniel L Baker & Kevin M Gray. Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology 2017;234:427‐435.

59. Brian J Sherman, Nathaniel L Baker, Aimee L McRae‐Clark. Effect of oxytocin pretreatment on cannabis

outcomes in a brief motivational intervention. Psychiatry Research 2017;249:318‐320 60. Brian Sherman, Aimee L McRae‐Clark, Nathaniel L Baker, Susan Sonne, Therese K Killeen, Kasie Cloud,

Kevin M Gray. Gender differences among treatment‐seeking adults with cannabis use disorder: clinical profiles of women and men enrolled in the Achieving Cannabis Cessation‐Evaluating N‐acetylcysteine Treatment (ACCENT) study. The American Journal on Addictions 2017; 26(2):136‐144.

61. Lisa J Germeroth, Matthew J Carpenter, Nathaniel L Baker, Brett Froeliger, Steven D LaRowe, Michael E

Saladin. A Brief Memory Updating Intervention Significantly Attenuates Smoking Behavior. JAMA Psychiatry 2017; 74(3);214‐223.

62. Samar M Hammad, Nathaniel L Baker, Jad M El Abiad, Stefanka D Spassieva, Jason S Pierce, Barbara

Rembiesa, Jacek Bielawski, Maria F Lopes‐Virella, Richard L Klein. Increased Plasma Levels of Select Deoxy‐Ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study. NeuroMolecular Medicine 2017;19(1):46‐56.

Baker, Nathaniel L

- 10 - Last Updated 1/9/2018

63. Erin A McClure, Nathaniel L Baker, Matthew J Carpenter, Frank A Treiber, Kevin M Gray. Attitudes and interest in technology‐based treatment and the remote monitoring of smoking among adolescents and emerging adults. Journal of Smoking Cessation 2017;12(2):88‐98.

64. Kevin M Gray, Susan C Sonne, Erin A McClure, Udi E Ghitza, Abigail G Matthews, Aimee L McRae‐Clark,

Kathleen M Carroll, Jennifer S Potter, Katharina Wiest, Larissa J Mooney, Albert Hasson, Sharon L Walsh, Michelle R Lofwall, Shanna Babalonis, Robert W Lindblad, Steven Sparenborg, Aimee Wahle, Jacqueline S King, Nathaniel L Baker, Rachel L Tomko, Louise F Haynes, Ryan G Vandrey, Frances R Levin. A Randomized Placebo‐Controlled Trial of N‐Acetylcysteine for Cannabis Use Disorder in Adults. Drug and Alcohol Dependence 2017 August; 177:249‐257.

65. Caroline Vrana, Therese Killeen, Victoria Brandt, Jana Mastrogiovanni, Nathaniel L Baker. Rationale, Design, and Implementation of a Clinical Trial of a Mindfulness‐Based Relapse Prevention Protocol for the Treatment of Women with Comorbid Post Traumatic Stress Disorder and Substance Use Disorder. Contemporary Clinical Trials 2017 October; 61:108‐114.

66. Rachel L Tomko, Nathaniel L Baker, Erin A McClure, Susan C Sonne, Aimee L McRae‐Clark, Brian J Sherman, Kevin M Gray. Incremental Validity of Estimated Marijuana Grams as a predictor of Problems and Cannabinoid Biomarkers: Evidence from a Clinical Trial. Drug and Alcohol Dependence 2018 January;182:1‐7.

67. Nathaniel L Baker, Kelly J Hunt, Danielle R Stevens, Gabor Jarai, Glenn Rosen, Richard L Klein, Gabriel

Virella, Maria F Lopes Virella, and the DCCT/EDIC Research Group. The association between inflammatory markers and progression to kidney dysfunction: examining different assessment windows in type 1 diabetic subjects. Diabetes Care 2018 January;41(1):128‐135.

68. Megan M Moran‐Santa Maria, Brian J Sherman, Kathleen Brady, Nathaniel L Baker, J. Madison Hyer,

Chantelle Ferland, Aimee McRae‐Clark. Impact of endogenous progesterone on reactivity to yohimbine and cocaine cues in cocaine‐dependent women. Pharmacology, Biochemistry and Behavior (2018) In Press.

69. Gregory L Sahlem, Nathaniel L Baker, Mark S George, Robert Malcolm, Aimee L McRae‐Clark. Repetitive

transcranial magnetic stimulation (rTMS) can be safely and feasibly applied to the dorsolateral prefrontal cortex (DLPFC) of non‐treatment seeking heavy cannabis users. The American Journal of Drug and alcohol Abuse (2018) In Press.

70. Lindsay M Squeglia, Rachel L Tomko, Nathaniel L Baker, Erin A McClure, George A Book, Kevin M Gray.

The effect of N‐acetylcysteine on alcohol use during a cannabis cessation trial. Drug and Alcohol Dependence (2018) In Press.

Non‐Peer Reviewed Articles 1. Nathaniel L Baker, Kevin M Gray. Jittering: A SAS® Macro to Shift Overlapping Plots. Proceedings of the Southeast SAS Users Group (SESUG) 2009 Conference; Statistics and Data Analysis Paper 002 (SD‐002). Cary, NC: SAS Institute Inc. October 2009.

Manuscripts Submitted and in Preparation:

Baker, Nathaniel L

- 11 - Last Updated 1/9/2018

1. Nathaniel L Baker, Kevin M Gray, Kristen Morella, Brian J Sherman, Amanda M Wagner, Aimee L McRae‐Clark. Biological correlates of self‐reported new and continued abstinence in cannabis cessation treatment clinical trials. Submitted to Drug and Alcohol Dependence.

2. Nathaniel L Baker, Viswanathan Ramakrishnan, Michael E Saladin, Erin M McClure, Matthew J Carpenter, and Kevin M Gray. Estimating Components of Dynamic Changes in Ovarian Hormones in Freely Cycling Female Smokers. In Progress.

3. Gregory L Sahlem, Nathaniel L Baker, Robert Malcolm, Aimee L McRae‐Clark. High Impulsivity Correlates with Cannabis Cue‐Induced Craving in a Non‐Treatment Seeking Cohort of Heavy Cannabis Users. Submitted to Psychiatry Research.

4. Michael E. Saladin, Kevin M. Gray, Aimee L. McRae‐Clark, Steven D. LaRowe, Sharon D. Yeatts, Nathaniel L Baker, Karen J. Hartwell, and Kathleen T. Brady. PTSD/reconsolidation. Under Revision.

5. Christina M Sheerin, Nathaniel L Baker, Ananda B Amstadter, Aimee L McRae‐Clark. Oxytocin effects on

stress and craving response in cannabis users moderated by adverse childhood events. Under Revision. 6. Angela Moreland, Delisa Brown, Nathaniel L Baker, Aimee McRae‐Clark. Is Parenting Really That

Stressful? Daily Behavior Stress in Drug Using Parents Compared to Non‐Parents. Under Revision.

7. Erin M McClure, Nathaniel L Baker, Susan Sonne, Kevin M Gray. Characterization of tobacco use at screening within a multi‐site medication‐assisted cannabis cessation trial. In Progress.

8. Erin M McClure, Nathaniel L Baker, Susan Sonne, Kevin M Gray. Tobacco use during cannabis cessation: Prevalence, changes in use, and influence on cannabis abstinence in a National Drug Abuse Treatment Clinical Trials Network study. In Progress

9. Brian J Sherman, Nathaniel L Baker, Lindsay M Squeglia, Aimee L McRae‐Clark. The effect of approach bias modification on cannabis cue‐reactivity and cannabis outcomes: a pilot study. Submitted to the journal of substance abuse research.

10. Lisa J Germeroth, Nathaniel L Baker, Michael E Saladin. Intolerance for smoking abstinence among nicotine deprived, treatment seeking smokers. In progress.

11. Karen J Hartwell, James R Walker, Nathaniel L Baker, Amanda M Wagner, Aimee L McRae‐Clark. Measurement of medication adherence using smart capsules. In progress.

Conference, Symposium, Continuing Education and Short Corse Attendance 2003 Joint AMS / MAA SE Regional Conference, Clemson SC 2005 Joint AMS / MAA National Meeting, Atlanta GA 2008 Southeast SAS Users Group Meeting, St. Petersburg FL 2009 Frontiers in Quantitative Methods for Cancer Research, Medical College of Georgia Short Course, Augusta GA

Baker, Nathaniel L

- 12 - Last Updated 1/9/2018

2009 Southeast SAS Users Group Meeting, Birmingham AL (Oral Presenter) 2010 American Diabetic Association Scientific Symposium, Orlando FL 2011 American Diabetic Association Scientific Symposium, San Diego CA (Oral Presenter) 2012 American Diabetic Association Scientific Symposium, Philadelphia PA (Oral Presenter) 2013 Workshops in Quantitative Research Methodology, Summer Research Institute, Short Course on Longitudinal/Multilevel Modeling, May, 2013, MUSC, Charleston, SC 2013 Statistics in Medicine (HRP258‐MOOC; Dr. Kristin Sainani), Certificate with Distinction, June 10‐

Aug 16, 2013 Stanford University 2013 International Conference on Health Policy Statistics, Chicago IL 2013 ICHP Workshop on Extended Mixed Models for Ecological Momentary Assessment (EMA) Data,

Dr. Don Hedeker, October 2013, Chicago IL 2014 Statistical Analysis of fMRI Data (MOOC; Dr. Martin Lindquist), Certificate with Distinction,

February 24‐April 6, Johns Hopkins University 2015 American Diabetic Association Scientific Symposium, Boston MA (Poster Presenter) 2015 Using Propensity Scores to Effectively Design and Analyze Observational Studies (American

Statistical Association Short Course; Dr. Thomas E Love), November 6, 2015, Medical University of South Carolina

2016 American Diabetic Association Scientific Symposium, New Orleans LA (Poster Presenter) 2016 National Institute of Drug Abuse Conference on Clinical Trial Endpoints of Therapeutics for

Cannabis Use Disorders (CUDs), September 12th, 2016, Bethesda, MD (Invited Presenter) 2017 American Diabetic Association Scientific Symposium, San Diego CA (Poster Presenter)

Current Extramural Funding R01 DK099177‐01A1 (Lopes‐Virella, PI) 07/01/2013‐6/30/2018 NIH/NIDDK $383,666 Annual Direct Costs Role of Sphingolipids in the Development of Diabetic Nephropathy This proposal intends to study the role and response of ceramides and sphingolipids in the development and progression of nephropathy in type 1 diabetes. Role: Co‐Investigator 1K24 DA038240‐01 (McRae‐Clark, PI) 7/1/2014‐6/30/2019 NIH/NIDA Mid‐Career Award in Patient Oriented Drug Abuse Research The objective of this Midcareer Investigator Award in Patient‐Oriented Research is to provide support for protected time so that Dr. Aimee McRae‐Clark can develop a more formal, intensive program of mentored clinical research training and career development activities to promote junior scholars in the area of drug abuse and addiction. Particular emphasis will also be placed on increasing the participation of underrepresented minorities conducting patient‐oriented research. Role: Statistician 1R01 DA035247‐01 (Saladin, PI) 04/01/2013 – 03/31/2018 NIH/NIDA $347,689 Annual Direct Costs Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity & Use The purpose of this project is to investigate the augmentation of the disruption of reconsolidation (DoR) effect by (a) doubling the number of propranolol medicated retrieval sessions of CCE, and (b) increasing the dose of propranolol. This is expected to enhance the response dampening ‘signal’ detected in the R21 and assess its durability, generalizability and effects on cocaine use.

Baker, Nathaniel L

- 13 - Last Updated 1/9/2018

Role: Co‐Investigator P50 DA016511‐11 (Brady, PI) 09/01/2012 – 07/31/2017 NIH/NIAMS $750,000 Annual Direct Costs Specialized Center of Research (SCOR) on Sex and Gender Factors Affecting Women's Health The purpose of this project is to study gender differences in response to cocaine related cues and negative emotional states in men and women. Role: Co‐Investigator

1U01 DA031779‐01A1 (Gray, PI) 06/01/2012‐05/31/2017 NIH/NIDA $428,356 Annual Direct Costs A Randomized Trial of Varenicline for Adolescent Smoking Cessation This primary goal of the study will be to examine the efficacy of varenicline, compared with placebo, for smoking cessation in adolescent smokers. Secondarily, the study will assess the safety of varenicline in an adolescent population. Role: Co‐Investigator

BX0001683‐01 (Lopes‐Virella, PI) 04/01/2013‐03/31/2017 Biomedical Lab R&D Merit $199,300 (1st year; 150,000/remaining) Department of Veterans Affairs Modified LDL, Immunity and the Development of Diabetic Complications This project will compare the activation patterns of macrophages exposed to modified LDL immune complexes (IC) and the effect of these IC on the survival/ apoptosis of the same cells. In this project we will also perform measurements of novel plaque instability biomarkers in a subgroup of the VADT cohort to determine whether or not they can identify patients at high risk for acute MI. Role: Statistician 1I01 BX001282‐01A2 (Brady, PI) 10/01/2014‐09/30/2018 Psychological Health and social Reintegration RR&D Merit $250,000 Department of Veterans Affairs Mindfulness‐Based Recovery in Veterans with Substance Use Disorder Role: Co‐Investigator K01 DA036739 07/01/2014‐06/30/2019 NIH/NIDA Technological Innovations for the Remote Monitoring of Smoking in Adolescents This career development grant will develop Dr. McClure’s expertise in mobile health and adolescent smoking and addiction, and will evaluate the accuracy and acceptability of a remote monitoring system to detect smoking and relapse in adolescents. Priority/impact score of 11, 2nd round. Role: co‐Investigator American Cancer Society Institutional Research Grant at MUSC, Pilot Project 04/01/2014‐12/31/2014 Technological Innovations for the Remote Monitoring of Smoking in Adolescents This pilot project will develop and evaluate a remote monitoring technology to detect smoking and relapse in adolescents. Role: Statistician

Baker, Nathaniel L

- 14 - Last Updated 1/9/2018

Queens Univ. Belfast (Klein; Site PI) 07/01/2013‐06/30/2017 $32,470 Lipoproteins and Pedf and the Vascular Complications of Diabetes Role: Statistician (5%) CX001288 (Back) 10/01/2015‐09/30/2019 Department of Veterans Affairs $9,528 CAP ‐ Doxazosin in the Treatment of Co‐Occurring PTSD and Alcohol Use Disorders Role: Statistician (10%) UG1 DA013727 (Brady, PI) 09/30/2000‐05/31/2020 NIH/NIDA $107,157 Southern Consortium Node of the Clinical Trials Network (CTN) This is a cooperative agreement between NIDA, treatment providers, and researchers throughout the nation in which science is being utilized as a vehicle to improve the treatment of addictions. It is the goal of the Southern Consortium Node to work collaboratively with NIDA, the NIDA‐ Clinical Trials Network (CTN) contracted coordinating and data centers, and other CTN Nodes in conducting and directing multi‐site clinical trials and dissemination efforts. Role: Statistician (10%) R01 DA038700‐01A1 (Froeliger, PI) 07/02/2015‐6/30/2020 NIH/NIDA $XXX,XXX Translational Neuropsychopharmacology Research of Nicotine Addiction (SUGARCUBE) The proposed study is to investigate limbic‐striatal and corticostriatal circuits involved in nicotine addiction and determine the value of VRN+NAC for normalizing circuitry function and treating nicotine addiction. Role: Statistician (10%) R01 DA040968‐01 (Killeen, PI) 010/01/2015‐9/30/2020 NIH/NIDA $XXX,XXX Mindfulness Meditation for women with comorbid PTSD and SUD (MBRP) This is a behavioral development study to adapt a mindfulness meditation intervention to treat women with comorbid PTSD and substance use disorders enrolled in a community substance abuse intensive treatment program. Role: Statistician (10%)

PENDING RO1 DA042144 (Gray) 07/01/2016‐06/30/2021 1.2NIH/NIAAA $425,000 N‐Acetylcysteine and Contingency Management for Youth Cannabis Use Disorder The majority of young cigarette smokers fail to achieve abstinence during a quit attempt, even with the assistance of evidence‐based treatments. Given that relapse to smoking is the most likely outcome of any given quit attempt, there is a pressing need to expand treatment options for tobacco use disorder to improve long‐term outcomes. The current study will assess N‐acetylcysteine (NAC) and CM in a 2x2 design as a potential pharmacotherapy for tobacco use disorder by testing its role in the initiation of abstinence and relapse prevention. Mixed results from the clinical literature on NAC’s efficacy suggest that the knowledge to be gained from the proposed application is essential prior to implementing NAC in larger randomized controlled trials.

Baker, Nathaniel L

- 15 - Last Updated 1/9/2018

Results from this trial may have notable impact, as NAC could be used as part of combination treatment with abstinence‐targeted pharmacotherapies or behavioral interventions. Role: Statistician SCORE: 20 PERCENTILE: 5% R34 DA042228 (McClure) 07/01/2016‐06/30/2017 1.2NIH/NIDA $175,000 Evaluating N‐acetylcysteine as a pharmacotherapy for tobacco use disorder The majority of cigarette smokers fail to achieve abstinence during a quit attempt, even with the assistance of evidence‐based treatments. Given that relapse to smoking is the most likely outcome of any given quit attempt, there is a pressing need to expand treatment options for tobacco use disorder to improve long‐term outcomes. The current study will assess N‐acetylcysteine (NAC) as a potential pharmacotherapy for tobacco use disorder by testing its role in the initiation of abstinence and relapse prevention. Mixed results from the clinical literature on NAC’s efficacy suggest that the knowledge to be gained from the proposed application is essential prior to implementing NAC in larger randomized controlled trials. Results from this trial may have notable impact, as NAC could be used as part of combination treatment with abstinence‐targeted pharmacotherapies or behavioral interventions. Role: Statistician SCORE: 21 PERCENTILE: 7% R01 AA025086 (Back) 07/01/2016‐06/30/2021 NIH/NIAAA $434,201 A Randomized Controlled Trial of N‐Acetylcysteine for Alcohol Use Disorder and Comorbid PTSD Alcohol use disorder (AUD) and post‐traumatic stress disorder (PTSD) are chronic psychiatric conditions that frequently co‐occur. There are substantial gaps in the evidence base regarding the treatment of co‐occurring AUD/PTSD and there is an immediate need forth development of effective, evidence‐based interventions. The proposed study will examine the efficacy of the antioxidant N‐acetylcysteine (NAC) as a medicationwhich has the potential to reduce both AUD and PTSD severity. The findings from this study may open a new avenue for treatment of this common and complex comorbidity. The proposed study has the potential to significantly improve the standard of patient care, advance the comorbidity science in this area, and decrease publichealth expenditures Role: Statistican SCORE: 19 PERCENTILE: 4% R01 CA207229 (Toll) 07/01/2016‐06/30/2021 NIH/NCI $461,388 Gain‐framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening The Center for Medicare and Medicaid Services (CMS) recently approved annual lung cancer screening as a benefit for individuals: (1) ages 55‐77 years old; (2) asymptomatic (no signs of lung cancer illness); (3) tobacco smoking history of at least 30 pack‐years; and (4) report current smoking or quit smoking within the past 15 years. While one might hypothesize that simply having a CT scan may promote cessation, evidence suggests that having a scan increases quit rates only slightly, if there is any increase at all. Most patients presenting for screening will have variable motivation to quit smoking, with many of them lacking motivation to quit. Studying smoking cessation interventions in the context of lung cancer screening has the potential to improve cessation rates for this high‐risk group of smokers. Role: Statistician

Baker, Nathaniel L

- 16 - Last Updated 1/9/2018

SCORE: PERCENTILE: 27%

R01 DA039905 (Mcrae‐Clark) 09/01/2016‐08/31/2021 NIH/NIDA $369,095 Oxytocin Augmentation of Motivational Enhancement Therapy for Cannabis Use Disorders The neuropeptide oxytocin has been shown to modulate cannabis craving as well as be related to emotional constructs such as attachment and trust. It is therefore possible that oxytocin pretreatment could improve cannabis use outcomes following a therapy intervention, particularly one focused on empathy and providing support. This project will investigate the impact ofoxytocin augmentation on cannabis use and craving following a motivational enhancement therapy intervention, and explore how factors such as trauma exposure and gender may impact this response. Role: Statistican K24 DA040194 (Gray) 04/01/2016‐03/31/2021 NIH/NIDA $173,269 Mentoring in Youth Cannabis and Tobacco Use Disorder Research The objective of this Midcareer Investigator Award in Patient‐Oriented Research is to provide dedicated support for Dr. Kevin M. Gray to develop an intensive mentorship and career development program for promising early investigators focused on addressing cannabis and tobacco use disorders in youth. This is a critically underserved area of significant public health concern, and Dr. Gray’s track record indicates that he is uniquely positioned to make significant, longstanding contributions to the field via this award mechanism Role: Statistican eTect, Inc. (McRae‐Clark) 08/01/2016‐07/31/2018 Validation of the ID‐Cap System for Clinical Monitoring and Intervention Role: Statistician R01 DK099180 (Hunt) 07/01/2016‐06/30/2021 NIH/NIDDK Vascular Outcomes in African Americans with Diabetes: Project SuGAR and REGARDS Diabetes disproportionately affects minority populations, with African Americans having a two to three fold increased risk, an earlier age of onset and greater years of life lost than whites. Precision Medicine builds off our ever increasing ability to sequence the human genome, perform biomedical analyses and analyze large databases. The proposed study combines aspects from each of these areas, building off established cohorts ultimately to develop tailored algorithms for heart disease, stroke and kidney disease in African Americans with diabetes. As the diabetes burden on society increases it is imperative to improve our understanding of its consequences in minority populations. R34 Unnumbered 07/01/2013‐06/30/2016 NIH/NIDA $182,596 Annual Direct Costs Mindfulness Meditation for Women with PTSD and SUD in a Community Setting This study explores the use of Mindfulness Based Relapse Prevention (MBRP), an efficacious eight session group therapy for the treatment of individuals with substance use disorders, in women with comorbid PTSD and SUD enrolled in community substance abuse treatment. Role: Co‐Investigator (15% Effort) R21 DK099177 07/01/2014‐06/30/2016 NIH/NIMH $150,000 Annual Direct Costs Vigabatrin for the Treatment of Posttraumatic Stress Disorder

Baker, Nathaniel L

- 17 - Last Updated 1/9/2018

The proposed study is a randomnized double‐blind trial to preliminarily evaluate the efficacy and safety of vigabatrin in individuals with PTSD. Role: Co‐Investigator (10% Effort) Recently Completed 1R21 DA034089‐01 07/01/2012‐05/31/2014 (NCE 2015) NIH/NIDA $150,000 Annual Direct Costs Vilazodone Treatment for Marijuana Dependence Results from this study could lead to the development of a new pharmacotherapy for marijuana dependence and increase our knowledge of a potential genetic biomarker for prediction of outcomes. Role: Statistician 5R01 DA026782‐04 08/15/2009‐05/31/2014 (NCE 2015) NIH/NIDA $240,075 Annual Direct Costs Buspirone Treatment for Marijuana Dependence Results from this study could lead to the development of a new pharmacotherapy for marijuana dependence. Increase our knowledge of a potential genetic biomarker for prediction of outcomes, and improve clinical trial methodology in the investigation of marijuana dependence. Role: Statistician 1R21 DA035993‐01 08/01/2013 – 07/31/2015 NIH/NIDA $150,000 Annual Direct Costs Reducing Smoking Cue Reactivity & Behavior Via a Retrieval‐Extinction Mechanism This study will examine the effects of two sessions of retrieval‐extinction training in smokers who are making a quit attempt. Effects of the training on smoking craving and cue reactivity, and on indices of smoking, will be assessed. It is expected that the smoking‐cue retrieval feature of this training will result in significant and enduring reductions in craving and reactivity to smoking cues and have a favorable impact on smoking. Role: Co‐Investigator

U24 DK076169 10/01/2013‐09/30/2014 NIH/NIDDK through Georgia Regents University (DiaComp) $47,816 Annual Direct Costs Association of Plasma Deoxysphingolipids with Neuropathy in the DCCT/EDIC Cohort The aim of this proposal is to generate pilot data investigating the association of deoxysphingolipids with neuropathy in type 1 diabetic patients. Role: Statistician N01 DA‐11‐1145 10/01/2013‐10/01/2014 NIH/NIDA AACAP Resident Research Award Cognitive Performance in an Adolescent Marijuana Cessation Pharmacotherapy Trial/ Passed Through the American Academy of Child Psychiatry The aim of this proposal is to examine cognitive performance among adolescents with marijuana dependence enrolled in a pharmacotherapy trial Role: Statistician 5R01DK081352‐03 09/01/2008‐07/31/2012 DHHS/NIH/NIDDK $357,032 Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus

Baker, Nathaniel L

- 18 - Last Updated 1/9/2018

The goal of this research is to elucidate the value of selected biomarkers in predicting the development of micro‐ and macro‐vascular complications in Type 1 diabetes and to determine if several risk factors, some unique to diabetes, may interact to augment vascular risk. Role: Statistician

R01DK088778 07/01/2010‐06/30/2012 NIH/NIDDK $125,000 Longitudinal Assessment of LDL Immune Complexes and Type 1 Diabetes Complications The goal of this project is to complete secondary data analysis to study the epidemiology of LDL immune complex (IC) measurements in relation to micro‐ and macro‐vascular complications in 520 DCCT/EDIC participants with these biomarkers measured at four time points spanning 22 years. Role: Statistician

5P50DA016511‐10 09/30/2002‐06/30/2012 NIH/NIDA $568,161 SCOR on Sex and Gender Factors Affecting Women’s Health This center grant is funded through a partnership between ORWH and NIH to develop and conduct innovative, interdisciplinary and collaborative research investigating substance use disorders among women. Role: Statistician

curiculum vitae - the medical university of south …people.musc.edu/~nab42/baker, nl cv.pdf ·...

Documents